Upgrade to SI Premium - Free Trial

Bristol-Myers Squibb (BMY) Offers Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma on Partial Clinical Hold

September 6, 2017 5:26 PM
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on CA209602 (CheckMate-602), CA209039 (CheckMate-039) and CA204142 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles